{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/achieving-diversity-drug-development-programs-obesity#webpage",
"url": "https://www.fortrea.com/insights/achieving-diversity-drug-development-programs-obesity",
"name": "Achieving Diversity in Drug Development Programs for Obesity | Fortrea White Paper",
"description": "This Fortrea white paper explores the importance of achieving diversity in drug development programs within obesity research and the strategies used to improve representation across clinical trials. The content focuses on diverse patient recruitment, inclusive clinical trial participation, health equity in clinical research, and addressing barriers that affect representation within obesity drug development studies. The white paper highlights challenges associated with underrepresented populations, patient engagement, trial accessibility, and developing inclusive trial design approaches that support broader participation across obesity clinical research programs. Fortrea discusses strategies designed to strengthen diversity in clinical trials, improve representation across patient populations, and support equitable participation throughout obesity drug development research. By integrating diversity-focused recruitment approaches with inclusive research planning and patient-centered clinical trial strategies, the white paper provides insights into advancing representation and health equity within obesity clinical research programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Achieving Diversity in Drug Development Programs for Obesity",
"item": "https://www.fortrea.com/insights/achieving-diversity-drug-development-programs-obesity"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/achieving-diversity-drug-development-programs-obesity#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/achieving-diversity-drug-development-programs-obesity#webpage"
},
"headline": "Achieving Diversity in Drug Development Programs for Obesity Research | Fortrea White Paper",
"description": "This Fortrea white paper explores the importance of achieving diversity in drug development programs within obesity research and the strategies used to improve representation across clinical trials. The content focuses on diverse patient recruitment, inclusive clinical trial participation, health equity in clinical research, and addressing barriers that affect representation within obesity drug development studies. The white paper highlights challenges associated with underrepresented populations, patient engagement, trial accessibility, and developing inclusive trial design approaches that support broader participation across obesity clinical research programs. Fortrea discusses strategies designed to strengthen diversity in clinical trials, improve representation across patient populations, and support equitable participation throughout obesity drug development research. By integrating diversity-focused recruitment approaches with inclusive research planning and patient-centered clinical trial strategies, the white paper provides insights into advancing representation and health equity within obesity clinical research programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2024-10/GettyImages-1047624924%20%281%29.webp"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-14",
"dateModified": "2024-10-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/WP_0052_Obesity.pdf",
"encodingFormat": "application/pdf"
}
}
]
}